GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vanda Pharmaceuticals Inc (STU:VM4) » Definitions » E10

Vanda Pharmaceuticals (STU:VM4) E10 : €0.19 (As of Dec. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Vanda Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Vanda Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2024 was €-0.076. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €0.19 for the trailing ten years ended in Dec. 2024.

During the past 12 months, Vanda Pharmaceuticals's average E10 Growth Rate was -25.90% per year. During the past 3 years, the average E10 Growth Rate was 88.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Vanda Pharmaceuticals was 88.20% per year. The lowest was 54.00% per year. And the median was 75.30% per year.

As of today (2025-03-17), Vanda Pharmaceuticals's current stock price is €4.54. Vanda Pharmaceuticals's E10 for the quarter that ended in Dec. 2024 was €0.19. Vanda Pharmaceuticals's Shiller PE Ratio of today is 23.89.

During the past 13 years, the highest Shiller PE Ratio of Vanda Pharmaceuticals was 523.00. The lowest was 10.09. And the median was 26.82.


Vanda Pharmaceuticals E10 Historical Data

The historical data trend for Vanda Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vanda Pharmaceuticals E10 Chart

Vanda Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.06 0.03 0.16 0.24 0.19

Vanda Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.24 0.32 0.43 0.39 0.19

Competitive Comparison of Vanda Pharmaceuticals's E10

For the Biotechnology subindustry, Vanda Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vanda Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vanda Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Vanda Pharmaceuticals's Shiller PE Ratio falls into.



Vanda Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Vanda Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.076/133.1571*133.1571
=-0.076

Current CPI (Dec. 2024) = 133.1571.

Vanda Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201503 -0.222 99.621 -0.297
201506 -0.116 100.684 -0.153
201509 -0.196 100.392 -0.260
201512 -0.321 99.792 -0.428
201603 -0.260 100.470 -0.345
201606 -0.098 101.688 -0.128
201609 -0.009 101.861 -0.012
201612 -0.009 101.863 -0.012
201703 -0.159 102.862 -0.206
201706 -0.027 103.349 -0.035
201709 -0.084 104.136 -0.107
201712 -0.034 104.011 -0.044
201803 0.049 105.290 0.062
201806 0.077 106.317 0.096
201809 0.111 106.507 0.139
201812 0.167 105.998 0.210
201903 -0.009 107.251 -0.011
201906 0.186 108.070 0.229
201909 1.671 108.329 2.054
201912 0.072 108.420 0.088
202003 0.009 108.902 0.011
202006 0.142 108.767 0.174
202009 0.093 109.815 0.113
202012 0.115 109.897 0.139
202103 0.126 111.754 0.150
202106 0.141 114.631 0.164
202109 0.119 115.734 0.137
202112 0.106 117.630 0.120
202203 -0.100 121.301 -0.110
202206 0.047 125.017 0.050
202209 0.061 125.227 0.065
202212 0.113 125.222 0.120
202303 0.056 127.348 0.059
202306 0.028 128.729 0.029
202309 0.002 129.860 0.002
202312 -0.037 129.419 -0.038
202403 -0.064 131.776 -0.065
202406 -0.074 132.554 -0.074
202409 -0.081 133.029 -0.081
202412 -0.076 133.157 -0.076

Add all the adjusted EPS together and divide 10 will get our e10.


Vanda Pharmaceuticals  (STU:VM4) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Vanda Pharmaceuticals's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=4.54/0.19
=23.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Vanda Pharmaceuticals was 523.00. The lowest was 10.09. And the median was 26.82.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Vanda Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Vanda Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Vanda Pharmaceuticals Business Description

Traded in Other Exchanges
Address
2200 Pennsylvania Avenue NW, Suite 300 E, Washington, DC, USA, 20037
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Vanda Pharmaceuticals Headlines

No Headlines